{
    "name": "nitroglycerin PO",
    "comment": "Rx",
    "other_names": [
        "glyceryl trinitrate PO"
    ],
    "classes": [
        "Nitrates",
        "Angina"
    ],
    "source": "https://reference.medscape.com/drug/glyceryl-trinitrate-po-nitroglycerin-po-342281",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: not known whether the drug crosses into breast milk, use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known whether the drug crosses into breast milk, use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, acute MI, severe anemia",
                "Recent use (within several days) of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, or vardenafil) may cause dangerously low hypotension; the time course of the interaction appears to be related to the PDE-5 inhibitor half-life",
                "Coadministration with soluble guanylate cyclase stimulators, including riociguat"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in increased ICP (eg, head trauma, cerebral hemorrhage; potential contraindication), hyperthyroidism, increased IOP, postural hypotension, volume depletion, low systolic BP",
                "Do not change brands unintentionally as not all are bioequivalent",
                "Treat drug-induced headache with aspirin or acetaminophen",
                "Provide nitrate-free interval (10-12 hr or overnight) to avoid development of tolerance",
                "Angina long term prophylaxis, NOT for acute relief",
                "Lack of burning/tingling does not indicate loss of potency",
                "Discontinue if blurred vision occurs",
                "Use supportive treatment in overdose",
                "Benefits of oral nitroglycerin in patients with acute myocardial infarction or congestive heart failure not established; if administered in these conditions, use careful clinical or hemodynamic monitoring to avoid hazards of hypotension and tachycardia; because effects of capsules are so difficult to terminate rapidly, not recommended in these settings",
                "Severe hypotension, particularly with upright posture, may occur with even small doses; should be used with caution in patients who may be volume depleted or who, for whatever reason, are already hypotensive; hypotension induced by therapy may be accompanied by paradoxical bradycardia and increased angina pectoris",
                "Therapy may aggravate angina caused by hypertrophic cardiomyopathy",
                "As tolerance to other forms of nitroglycerin develops, effect of sublingual nitroglycerin on exercise tolerance, although still observable, is somewhat blunted",
                "In industrial workers who have had long-term exposure to unknown (presumably high) doses of organic nitrates, tolerance clearly occurs; chest pain, acute myocardial infarction, and even sudden death have occurred during temporary withdrawal of nitrates from these workers, demonstrating existence of true physical dependence",
                "Some clinical trials in angina patients have provided nitroglycerin for about 12 continuous hours of every 24-hour day; during nitrate-free intervals in some of these trials, anginal attacks have been more easily provoked than before treatment, and patients have demonstrated hemodynamic rebound and decreased exercise tolerance; importance of these observations not known"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "avanafil",
            "description": {
                "common": "nitroglycerin PO, avanafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "riociguat",
            "description": {
                "common": "nitroglycerin PO, riociguat.\nEither increases effects of the other by additive vasodilation. Contraindicated. Coadministration of nitrates or nitric oxide donors is contraindicated due to risk of hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sildenafil",
            "description": {
                "common": "nitroglycerin PO, sildenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tadalafil",
            "description": {
                "common": "nitroglycerin PO, tadalafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "vardenafil",
            "description": {
                "common": "nitroglycerin PO, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabergoline",
            "description": {
                "common": "nitroglycerin PO increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "nitroglycerin PO increases effects of ergoloid mesylates by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergotamine",
            "description": {
                "common": "nitroglycerin PO increases effects of ergotamine by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofexidine",
            "description": {
                "common": "lofexidine, nitroglycerin PO.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "nitroglycerin PO increases effects of methylergonovine by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arginine",
            "description": {
                "common": "nitroglycerin PO, arginine. Mechanism: additive vasodilation. Use Caution/Monitor. Possible hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "nitroglycerin PO, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "nitroglycerin PO, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "nitroglycerin PO, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "nitroglycerin PO, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "nitroglycerin PO increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc, nitroglycerin PO.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracaine",
            "description": {
                "common": "tetracaine, nitroglycerin PO. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetylcysteine",
            "description": {
                "common": "acetylcysteine increases effects of nitroglycerin PO by Other (see comment). Minor/Significance Unknown. \nComment: Acetylcysteine may enhance vasodilatory effects of nitroglycerin."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetylcysteine (Antidote)",
            "description": {
                "common": "acetylcysteine (Antidote) increases effects of nitroglycerin PO by Other (see comment). Minor/Significance Unknown. \nComment: Acetylcysteine may enhance vasodilatory effects of nitroglycerin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Lightheadedness",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "N",
            "percent": null
        },
        {
            "name": "V",
            "percent": null
        },
        {
            "name": "Nervousness",
            "percent": null
        },
        {
            "name": "Xerostomia",
            "percent": null
        },
        {
            "name": "Methemoglobinemia",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Prolonged bleeding time",
            "percent": null
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "Unstable angina",
            "percent": null
        },
        {
            "name": "Rebound hypertension",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        }
    ]
}